Related Experiment Video

Updated: Feb 16, 2026

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition
11:48

Detection of Alternative Splicing During Epithelial-Mesenchymal Transition

Published on: October 9, 2014

13.4K

Therapeutic Applications of Targeted Alternative Splicing to Cancer Treatment

Jung-Chun Lin1,2

  • 1School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei 110, Taiwan. lin2511@tmu.edu.tw.

International Journal of Molecular Sciences
|December 29, 2017
PubMed

Insights

Impaired alternative splicing (AS) drives cancer and drug resistance. Targeting AS isoforms and splicing regulators offers new therapeutic strategies for distinct cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Alternative splicing (AS) plays a critical role in cellular processes.
  • Dysregulated AS is increasingly recognized as a driver of various diseases, notably cancer.
  • Alternatively spliced isoforms contribute to therapeutic resistance in cancer treatment.

Purpose of the Study:

  • To review recent findings on the impact of AS events in cancer biology.
  • To explore therapeutic strategies targeting alternatively spliced isoforms and splicing regulators.
  • To provide insights into novel treatment approaches for distinct cancers.

Main Methods:

  • Literature review of recent studies on alternative splicing in cancer.
  • Analysis of therapeutic strategies targeting splicing regulators and isoforms.
  • Synthesis of current knowledge on AS-driven cancer and drug resistance.

Main Results:

  • Impaired AS contributes to cancer pathogenesis.
  • AS generates isoforms linked to drug resistance.
  • Targeting AS offers potential therapeutic avenues.

Conclusions:

  • Alternative splicing is a significant factor in cancer development and treatment outcomes.
  • Targeting splicing machinery and its products presents a promising strategy for cancer therapy.
  • Further research into AS modulation could lead to improved cancer treatments.
Keywords:
alternative splicingoligonucleotidesmall molecule

More Related Videos

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells10:06

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells

Published on: April 26, 2017

9.5K
Identification of Alternative Splicing and Polyadenylation in RNA-seq Data08:35

Identification of Alternative Splicing and Polyadenylation in RNA-seq Data

Published on: June 24, 2021

6.5K

Related Concept Videos

Alternative RNA Splicing02:18

Alternative RNA Splicing

Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
25.3K
Alternative RNA Splicing02:18

Alternative RNA Splicing

5.2K
RNA Splicing01:32

RNA Splicing

Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
60.7K
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
214
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence01:19

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
189
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K